ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: 581 • 2012 ACR/ARHP Annual Meeting

    Examining a Role for Th17 Regulation and Toll-Like Receptor Signaling in Psoriatic Arthritis

    Fatima Abji1, Remy Pollock2, Fawnda Pellett3, Vinod Chandran4 and Dafna D. Gladman2, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis (PsA) is a seronegative inflammatory arthritis that develops in 30% of patients with cutaneous psoriasis (PsC). Joint inflammation in PsA is mediated…
  • Abstract Number: 2557 • 2012 ACR/ARHP Annual Meeting

    Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

    Christopher T. Ritchlin1, Alice B. Gottlieb2, Iain B. McInnes3, Lluis Puig4, Proton Rahman5, Shu Li6, Yuhua Wang6, Mittie K. Doyle7, Alan Mendelsohn8 and Arthur Kavanaugh9, 1Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 2Tufts Medical Center, Boston, MA, 3University of Glasgow, Glasgow, United Kingdom, 4Universitat Autònoma de Barcelona, 5Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 6Janssen Research and Development, LLC, PA, 7Janssen Research and Development, LLC/U of Penn, Spring House/Phila, PA, 8Immunology, Janssen Research & Development, LLC, Spring House, PA, 9UCSD School of Medicine, La Jolla, CA

    Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: Results of a Phase 3, multicenter, double-blind, placebo-controlled studyBackground/Purpose: Assess efficacy & safety…
  • Abstract Number: 590 • 2012 ACR/ARHP Annual Meeting

    The Association Between KIR3DL1 Alleles and Psoriatic Arthritis

    Remy Pollock1, Jeffrey Berinstein2, Arane Thavaneswaran2, Fawnda Pellett3, Dafna D. Gladman4 and Vinod Chandran5, 1Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 2Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 5Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Killer-cell immunoglobulin-like receptors (KIRs) are activating and inhibitory receptors that regulate NK and NK-T cells, which have been found in psoriatic plaques and synovial…
  • Abstract Number: 2558 • 2012 ACR/ARHP Annual Meeting

    Clinical Response, Drug Survival and Predictors Thereof Among 548 Switchers of Tumor Necrosis Factor Alpha Inhibitor Therapy in Psoriatic Arthritis. Results From the Danish Nationwide Danbio Registry

    Bente Glintborg1, Mikkel Østergaard2, Niels Steen Krogh3, Martin Dehn Andersen4, Ulrik Tarp4, Anne Gitte Loft4, Hanne M. Lindegaard5, Mette Holland-Fischer6, Henrik Nordin4, Dorte Vendelbo Jensen4 and Merete L. Hetland2, 1Copenhagen University Hospital Gentofte, Copenhagen, Denmark, 2Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 3ZiteLab ApS, Copenhagen, Denmark, 4DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, 5Department of Rheumatology, Odense University Hospital, Odense, Denmark, 6Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark

    Background/Purpose: Treatment with tumor-necrosis-factor-alpha inhibitors (TNFi) has improved the outcome in patients with psoriatic arthritis (PsA) who have failed treatment with synthetic disease modifying antirheumatic…
  • Abstract Number: 552 • 2012 ACR/ARHP Annual Meeting

    Simple Questions in the Dermatology Office May Reasonably Exclude, but Do Not Reliably Identify Psoriatic Arthritis Patients: Results From the Center of Excellence for Psoriasis and Psoriatic Arthritis

    Neha Garg1, Atul A. Deodhar2, Benjamin Ehst3, Andrew Blauvelt4, Jennifer Ku5 and Brian Truong4, 1Internal Medicine, Division of arthritis and rheumatic diseases, Oregon Health and Sciences University, Portland, OR, 2Oregon Health & Science University, Portland, OR, 3Dermatology, Oregon Health and Sciences University, Portland, OR, 4Oregon Health and Sciences University, Portland, OR, 5Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR

    Background/Purpose: Psoriatic arthritis (PsA) affects between 10-30% of patients with psoriasis (PsO), but is often missed when assessed in a dermatology clinic. The Center of…
  • Abstract Number: 2560 • 2012 ACR/ARHP Annual Meeting

    Response and Drug Survival of 1st TNF-Inhibitor in 440 Patients with Psoriatic Arthritis – What Is the Role of Co-Medication with Methotrexate?

    Karen M. Fagerli1, Elisabeth Lie2, Désirée van der Heijde3, Marte S. Heiberg4, Erik Rødevand5, Åse S. Lexberg6, Synnøve Kalstad7, Knut Mikkelsen8 and Tore K. Kvien1, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Diakonhjemmet hospital, Oslo, Norway, 5Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, 6Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, 7Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway, 8Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway

    Background/Purpose: It is well established that methotrexate (MTX) co-medication improves efficacy of TNF-inhibitors (TNFi) in rheumatoid arthritis, while in ankylosing spondylitis it is widely accepted…
  • Abstract Number: 569 • 2012 ACR/ARHP Annual Meeting

    Ustekinumab Improves Arthritis-Related and Skin-Related Quality of Life in Patients with Active Psoriatic Arthritis: Patient Reported Outcomes From Randomized and Double Blinded Phase III Psummit I Trial

    Arthur Kavanaugh1, Iain B. McInnes2, Alice B. Gottlieb3, Lluis Puig4, Proton Rahman5, Christopher T. Ritchlin6, Shu Li7, Yuhua Wang7, Chenglong Han8, Alan Mendelsohn9 and Mittie K. Doyle7, 1UCSD School of Medicine, La Jolla, CA, 2Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 3Tufts Medical Center, Boston, MA, 4Universitat Autònoma de Barcelona, 5Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 6Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 7Janssen Research & Development, LLC, Spring House, PA, 8Johnson & Johnson Pharmaceutical Services, LLC., Malvern, PA, 9Immunology, Janssen Research & Development, LLC, Spring House, PA

    Ustekinumab Improves Arthritis-related and Skin-related Quality of Life in Patients with Active Psoriatic Arthritis: Patient Reported Outcomes from Randomized and Double Blinded Phase III PSUMMIT…
  • Abstract Number: 2561 • 2012 ACR/ARHP Annual Meeting

    Switching Between TNF-Inhibitors in Psoriatic Arthritis: Data From the NOR-DMARD Study

    Karen M. Fagerli1, Elisabeth Lie2, Désirée van der Heijde3, Marte S. Heiberg4, Åse S. Lexberg5, Knut Mikkelsen6, Erik Rødevand7, Synnøve Kalstad8 and Tore K. Kvien1, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Diakonhjemmet hospital, Oslo, Norway, 5Department of Rheumatology, Vestre Viken, Drammen, Norway, 6Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 7Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, 8Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway

    Background/Purpose: Although TNF-inhibitors (TNFi) have proven efficacy in psoriatic arthritis (PsA), some patients do not respond to or do not tolerate their first TNFi. The…
  • Abstract Number: 531 • 2012 ACR/ARHP Annual Meeting

    Developmen and Validation of a New Instrument to Asess Health Related Quality of Life in Psoriasis Arthritis: The Vitacora Questionnaire

    Juan Carlos Torre-Alonso1, J. Santos-Rey2, JM Ruiz-Martin3, P. Valdazo-De Diego4, Mireia Moreno5 and Juan-Antonio Fernández6, 1Unit Rheumatology, Hospital Monte Naranco, Oviedo, Spain, 2Rheumatology, Toledo, Spain, 3Rheumatology, Viladecans, Spain, 4Rheumatology, Zamora, Spain, 5Rheumatology, Corporació Sanitària Parc Taulí, Sabadell, Spain, 6MP, Oviedo, Spain

    Background/Purpose: To develop and validate a specific questionnaire to measure health-related quality of life (HRQoL) in adults with psoriasis arthritis (PA) for use in clinical…
  • Abstract Number: 2562 • 2012 ACR/ARHP Annual Meeting

    Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Psummit I Study

    Arthur Kavanaugh1, Iain B. McInnes2, Alice B. Gottlieb3, Lluis Puig4, Proton Rahman5, Christopher T. Ritchlin6, Shu Li7, Yuhua Wang8, Alan Mendelsohn9 and Mittie K. Doyle7, 1UCSD School of Medicine, La Jolla, CA, 2University of Glasgow, Glasgow, United Kingdom, 3Tufts Medical Center, Boston, MA, 4Universitat Autònoma de Barcelona, 5Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 6Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 7Janssen Research & Development, LLC, Spring House, PA, 8Janssen Research & Development, LLC., Spring House, PA, 9Immunology, Janssen Research & Development, LLC, Spring House, PA

    Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-blind, Placebo-Controlled PSUMMIT I StudyBackground/Purpose: To assess efficacy and safety of ustekinumab…
  • Abstract Number: 536 • 2012 ACR/ARHP Annual Meeting

    Psoriasis and Psoriatic Arthritis in a Diverse Ethnic Cohort

    Gail S. Kerr1, Seema Qaiyumi2, John S. Richards2, Chesahna Kindred3, Sean A. Whelton4 and Florina M. Constantinescu5, 1Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, 2Rheumatology Section, Washington DC VA and Georgetown University, Washington, DC, 3Division of Dermatology, Howard University Hospital, Washington, DC, 4Division of Rheumatology, Georgetown University, Washington, DC, 5Rheumatology, Washington Hospital Center, Washington, DC

    Background/Purpose: Few clinical studies describe psoriasis (PSO) and psoriatic arthritis (PsA) in ethnic minority groups. Previous patient-reported data show PSO/PsA to be less frequent in…
  • Abstract Number: 2491 • 2012 ACR/ARHP Annual Meeting

    IL-17 Expression Is Low in Psoriatic Arthritis Synovium Compared to Expression in Matched Skin Lesions

    Jennifer Belasco1, Hiroshi Mitsui1, Mayte Suarez-Farinas1, James S. Louie2, Nathan Wei3, Nicholas Gulati1 and James G. Krueger1, 1Krueger Laboratory, The Rockefeller University, New York, NY, 2Rheumatology, UCLA School of Medicine, Los Angeles, CA, 3Arthritis Treatment Center, Frederick, MD

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease associated with psoriasis. It is known that treatment modalities are not equally effective for both skin…
  • Abstract Number: 537 • 2012 ACR/ARHP Annual Meeting

    The Association of alpha7 Nicotinic Acetylcholine Receptor Polymorphisms with Psoriatic Arthritis and Its Interaction with Smoking

    Lihi Eder1, Vinod Chandran2, Fawnda Pellett3, Remy Pollock4, Fatima Abji5, Adele Carty6, Sutharshini Shanmugarajah5, Cheryl Rosen7 and D. D. Gladman8, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 5Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 6Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 7Division of Dermatology, University of Toronto, Toronto western Hospital, Toronto, ON, Canada, 8Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Alpha7 nicotinic acetylcholine receptor (CHRNA7) is an ion channel that is gated by the binding of nicotinic ligands. Nicotine interacts with CHRNA7 leading to…
  • Abstract Number: 2223 • 2012 ACR/ARHP Annual Meeting

    Dysregulation of Chromatin Modification Enzymes in Psoriatic Arthritis

    Remy Pollock1, Fawnda Pellett2, Vinod Chandran3 and Dafna D. Gladman4, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 4Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Chromatin modification enzymes regulate gene expression by altering the accessibility of promoters to transcription factors. Several of these enzymes are dysregulated in rheumatoid arthritis,…
  • Abstract Number: 108 • 2012 ACR/ARHP Annual Meeting

    Disparity Between Sonographic and Clinical Criteria of Remission in Psoriasis Arthritis

    Christian Dejaco1, Rusmir Husic2, Judith Gretler3, Winfried B. Graninger4 and Josef Hermann2, 1Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, 2Rheumatology, Medical University Graz, Graz, Austria, 3Med Univ Klinik Graz, Auenbruggerplatz 15, Graz, Austria, 4Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria

    Background/Purpose: To compare ultrasound and clinical definitions of remission in psoriasis arthritis (PsA). Methods: Prospective study of 70 consecutive PsA patients [mean age 51.1 (±SD…
  • « Previous Page
  • 1
  • …
  • 79
  • 80
  • 81
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology